All Outputs (4)

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One? (2019)
Journal Article
Concordet, D., Gandia, P., Montastruc, J., Bousquet-Mélou, A., Lees, P., Ferran, A. A., & Toutain, P. (2019). Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?. Clinical Pharmacokinetics, 59, 1-5. https://doi.org/10.1007/s40262-019-00812-x

At the request of French Regulatory Authorities, a new formulation of Levothyrox® was licensed in France in 2017, with the objective of avoiding the stability deficiencies of an existing licensed formulation. Before launching the new formulation, an... Read More about Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?.

Semi-Mechanistic Modeling of Florfenicol Time-Kill Curves and in silico Dose Fractionation for Calf Respiratory Pathogens (2019)
Journal Article
Pelligand, L., Lees, P., Sidhu, P. K., & Toutain, P. (2019). Semi-Mechanistic Modeling of Florfenicol Time-Kill Curves and in silico Dose Fractionation for Calf Respiratory Pathogens. Frontiers in Microbiology, 10, https://doi.org/10.3389/fmicb.2019.01237

An important application of time-kill curve (TKC) assays is determination of the nature of the best PK/PD index (fAUC/MIC or fT% > MIC) and its target value for predicting clinical efficacy in vivo. VetCAST (the veterinary subcommittee of EUCAST) her... Read More about Semi-Mechanistic Modeling of Florfenicol Time-Kill Curves and in silico Dose Fractionation for Calf Respiratory Pathogens.

Levothyrox® new and old formulations: are they switchable for millions of patients? (2019)
Journal Article
Concordet, D., Gandia, P., Montastruc, J. L., Bousquet-Mélou, A., Lees, P., Ferran, A., & Toutain, P. L. (2019). Levothyrox® new and old formulations: are they switchable for millions of patients?. Clinical Pharmacokinetics, https://doi.org/10.1007/s40262-019-00747-3

Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media (2019)
Journal Article
Mead, A., Lees, P., Mitchell, J., Rycroft, A. N., Standing, J. F., Toutain, P. L., & Pelligand, L. (2019). Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media. Journal of Veterinary Pharmacology and Therapeutics, 42(1), 52-59. https://doi.org/10.1111/jvp.12719

For clinical isolates of bovine Mannheimia haemolytica and Pasteurella multocida, this study reports minimum inhibitory concentration (MIC) differences for tetracycline, oxytetracycline and doxycycline between cation‐adjusted Mueller‐Hinton broth (CA... Read More about Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media.